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Recent studies have highlighted the lack of consensus among
surgeons on the value of routine follow-up after apparently cura-
tive resection for colorectal cancer (Foster et al, 1987; Mella et al
1997). In theory, the aim of regular follow-up is to detect and treat
recurrence at an early stage in an attempt to improve survival.
Most studies have focused on the early detection of local recur-
rence amenable to surgery (Schiessel et al, 1986; Pollard et al,
1989; Camunas et al, 1991); however, there is increasing evidence
that this approach is both ineffective and costly (Bruinvels et al,
1994; Biggs and Ballantyne, 1994; Virgo et al, 1995).
Because the commonest site of recurrent disease is liver, an
alternative approach might be to focus on the early detection of
liver metastases. The aim of the present study was to determine
whether frequent liver imaging could detect liver metastases suit-
able for surgical or chemotherapeutic intervention at an asympto-
matic stage.
PATIENTS AND METHODS
Patients who had undergone potentially curative resections for
colorectal cancer between 1990 and 1996 were followed at a dedi-
cated clinic. Patients were reviewed at 3-month intervals for 2
years, and 6 monthly thereafter to 5 years. At each visit, the assess-
ment included medical history, clinical examination, rectal exami-
nation when appropriate, full blood count, liver function tests
and liver ultrasound. Computerized tomography (CT) scan of
abdomen and pelvis was performed annually. Additional investi-
gations were performed as appropriate.
Recurrences were classified as either locoregional or distant
metastases. If patients had tumour-related symptoms at the time of
detection, they were classified as having symptomatic recurrence.
Patients who developed recurrence were investigated and treated
as appropriate. Kaplan–Meier analysis was used to estimate
survival curves.
RESULTS
One hundred and fifty-seven patients were included in the study.
Sixty-eight (43%) were women and the mean age at diagnosis was
61 years. One hundred and two patients had colonic and 55 had
rectal cancers; of these, six (4%) patients had Dukes’ stage A
tumours, 94 (60%) had Dukes’ stage B and 57 (36%) had Dukes’
stage C tumours.
The mean patient follow-up is 45 months. None of the patients
with Dukes A tumours have recurred. To date, 18 (19%) patients
with Dukes B tumours and 32 (56%) with Dukes C tumours have
developed recurrent disease.
Fourteen (9%) patients developed local recurrence, a further
eight (5%) developed local recurrence in conjunction with
metastatic disease and 28 (56%) developed disseminated disease
without evidence of local recurrence. Of the 36 patients with
disseminated disease, the first site affected was the liver in 24 and
the lungs in a further four. The remaining eight patients recurred at
multiple sites. The majority (72%) of all recurrences were detected
within 30 months of primary surgery.
Of the 22 patients (ten rectal, 12 colonic) who developed local
recurrence, eight (36%) were asymptomatic at the time of detec-
tion. In contrast, of the 24 patients who developed histologically
proven liver metastases as the initial site of recurrence, 21 (87%)
were asymptomatic at the time of detection (Figure 1). Twelve
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patients had metastases diagnosed initially by both ultrasound and
CT scan and the remaining nine by CT alone. Two patients under-
went hepatic resection for limited metastatic disease. Nineteen
patients received chemotherapy; in nine of these, it was delivered
by intra-arterial infusion. Patients with liver metastases detected at
an asymptomatic stage had a median survival of 16 months (range
7–41 months) from the time of diagnosis, but survival in the group
of patients with symptomatic metastases was less than 4 months.
DISCUSSION
It has been traditional for surgeons to review their patients at
regular intervals after potentially curative resection. It is, however,
still not clear whether follow-up is of benefit. Enthusiasts believe
that intensive follow-up and early intervention will lead to a reduc-
tion in the number of deaths from colorectal cancer (Sugarbaker et
al, 1987; Safi and Beyer, 1993), whereas others point to the fact
that the value of follow-up remains unproven (Cochrane et al,
1980; Ballantyne and Modlin, 1988).
Until recently, there were no randomized clinical trials, the best
information being that from the meta-analysis performed by the
Dutch group (Bruinvels et al, 1994). In that analysis, the results of
seven non-randomized studies comparing routine and intensive
follow-up, designed to detect local recurrence, in over 3000
patients were evaluated. More asymptomatic recurrences were
detected and resected in the intensive follow-up group. However,
there was no significant difference in survival. When the analysis
was restricted to those studies that included carcinoembryonic
antigen (CEA) measurements, there was an apparent 9% increase
in 5-year survival in the intensively investigated group. The
authors interpreted this data cautiously, recognizing that a number
of biases were present.
Recently, three randomized trials comparing minimal with
intensive follow-up have been reported (Makela et al, 1995;
Ohlsson et al, 1995; Kjeldsen et al, 1997). In the largest of these
studies, 600 patients were randomized to either 6 monthly follow-
up or to follow-up visits at 5 and 10 years (Kjeldsen et al, 1997).
Investigations consisted of history and clinical examination, full
blood count and liver enzymes, faecal occult blood, chest radio-
graph and colonoscopy. No routine liver imaging was performed.
Recurrence rates were similar in both groups but the tumour recur-
rences in the intensive group were detected on average 9 months
earlier, often at an asymptomatic stage. Subsequently, more of
these patients underwent reoperation with curative intent. There
was, however, no difference in overall or cancer-related survival
between the two groups. The authors concluded that an intensive
follow-up plan is not justified considering the small proportion of
patients reoperated on for cure and the fact that no survival advan-
tage was detected.
An alternative approach has been evaluated by Northover et al
(1994). Patients undergoing potentially curative surgery were
randomized to an active intervention group or a control group.
CEA was measured in all patients at frequent intervals. In the
active intervention group, a rising CEA prompted further investi-
gation, including second-look laparotomy if appropriate.
Preliminary analysis has shown no difference in survival between
the two groups.
It may be that the above studies were based on a false premise,
namely that intensive follow-up would identify local recurrence at
a stage when it would be amenable to further potentially curative
surgery. However, the results of the above studies have shown that
although intensive follow-up detects more local recurrences at an
asymptomatic stage resulting in more reoperations, there is no
difference in overall or disease-related survival.
Follow-up designed to detect asymptomatic liver metastases
may be more effective. In our study, 21 of the 24 patients who
developed liver metastases were detected at an asymptomatic
stage; two underwent liver resection and 19 received
chemotherapy. It has been estimated that 600 patients per year in
the UK would be suitable for resection (Allen-Mersh, 1989);
however, the number of resections performed is considerably less.
It is worth noting that in the contemporary studies of liver resec-
tion, mortality is usually less than 5% and approximately 35% of
patients survive 5 years (Ballantye, 1993). These survival figures
are comparable or better than the results obtained after primary
surgery for many types of gastrointestinal surgery. Furthermore,
recent studies have shown that patients with disseminated disease
receiving systemic chemotherapy at an asymptomatic stage had
higher response rates, better quality of life and improved survival
compared with those patients in whom the administration of
chemotherapy was delayed until the patients became symptomatic
(Nordic Gastrointestinal Tumor Adjuvant Therapy Group, 1992).
Therefore, if liver metastases were diagnosed in more patients at a
point when they would be amenable to treatment, either resection
or chemotherapy, more long-term survivors might be anticipated.
Perhaps the time has come to readdress the question of follow-
up. In addition to those investigations designed to detect loco-
regional recurrence, future studies should include intensive liver
imaging during the first 3 years, with a view to identifying patients
suitable for either resection of liver secondaries or chemotherapy.
Further randomized trials comparing intensive with minimal
follow-up are currently being discussed at national and inter-
national level.
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